Germany-Results from a phase 3 trial of infliximab (Remicade, Centocor & Schering-Pough) in moderate to severe psoriasis show that monotherapy is "highly effective in the treatment of skin and ...

In a separate analysis from the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), among patients with severe psoriasis who were either dissatisfied ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

In certain types of arthritis, gut conditions, and plaque psoriasis, you may have higher-than-normal TNF levels. Infliximab works by blocking some forms of TNF. By blocking TNF, infliximab may ...

Back to Healio Patients with psoriasis being treated with Remicade had no significant change in clinical response and experienced minor adverse events when switching to an infliximab biosimilar ...

Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...

An integrated analysis of data from three pivotal trials shows that patients with severe psoriasis experienced significant improvements with Remicade therapy An integrated analysis of data from ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

UAB is expanding services for patients who seek relief from the itching, cracking and bleeding skin caused by psoriasis. Long-suffering patients are heralding the drug infliximab (Remicade), given as ...

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of infliximab for the treatment of adults with psoriasis, having considered evidence on the nature of the ...

You may use drugs such as adalimumab (Humira Pen, Humira Pen Crohn's-UC-HS Start, Humira Pen Psoriasis-Uveitis), etanercept (Enbrel), or infliximab (Avsola, Inflectra, Ixifi, Remicade, Renflexis).

For infliximab this trial period was 10 weeks (on the basis ... which corresponded to a subgroup with more severe psoriasis, defined as the 25% of people with the highest scores on the DLQI. In both ...